Japanese Reimbursement Granted For Naviscan's PET Scanner In Breast Applications
Naviscan's Japanese distributor, SCETI (Denis Group), has received notification of reimbursement approval from the Japanese Ministry of Health, Labour and Welfare, for its high-resolution, organ-specific PET scanner used in breast applications, effective July 1. The reimbursement criterion was based on the additional resolution and specificity obtained on PEM that cannot be determined in a typical whole body PET/CT examination.
High-resolution breast PET has an index lesion sensitivity of 93 to 96%, with a sensitivity for secondary lesion detection comparable with MRI, but with a 91% specificity, significantly better than MRI (p=0.032). This results in a measure of accuracy referred to as positive predictive value for PEM prompted biopsies of 66%, again significantly better than MRI (p=0.016). The third advantage is PEM guided biopsy can be performed on the same day and same dose of isotope, streamlining patient care.
The Naviscan PEM scanner is designed for for precisely characterising breast cancer (BC), enhancing surgical planning, monitoring patient response to chemotherapy and evaluating suspected recurrence. It is designed to show the metabolic phase of a lesion allowing for early BC diagnosis and assisting physicians in making optimal care decisions by providing an ability to distinguish between benign and malignant lesions.